Poly Medicure Limited · NSE:POLYMED
Poly Medicure — Q2 FY2024 Earnings Presentation
20 slides from Poly Medicure's earnings presentation, Sep 30, 2023
Slide 1: 2nd Quarter Results Presentation
2nd Quarter Results Presentation 30th September 2023 (Q2) mm x15 mm 2.00 SC- Infusion Therapy & Dialysis & Transfusion Diagnostics Cardiology Oncology Critical Care Vascular Access Renal Care System Poly Medicure Limited www.polymedicure.com
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Poly Medicure Limited (the “Company”) solely for your information and may not be distributed, reproduced, or redistributed or passed on directly or indirectly to any other person, whether within or outside your organization or firm, or published in wh
Slide 3: Table Of Content
Table Of Content Polymed at a Glance 4 Q2 FY 2023-24 Financial Trends 12 A success story spanning over 26 years 5 Financial Performance Comparison 14 Across the world 6 Way Forward... 15 Board of Directors 7 Shareholding Pattern 30th Sep, 2023 16 Executive Global Leadership 8 Focus on Sustainability
Slide 4: Polymed at a Glance
Polymed at a Glance 125+ 160+ 3000+ Countries Medical Devices Employee Base 350+ 30+ Sales Associates Clinical Specialists INR 1115 1 Billion+ Crores Devices Manufacturing Capacity per year Consolidated Revenue Largest Reach in Exporter 8,000+ of consumable Medical Hospitals in India devices for 10
Slide 5: A Success Story spanning over 26 Years
A Success Story spanning over 26 Years 2003 Joint Venture in Assuit, Egypt 2011 Company listed in National Stock 2018 Exchange Forayed in Renal Care 2024 (Dialysis) PolyHealth New 2004 Medical Inc. Sterilization Faridabad (US subsidiary of 2021 plant Plant 2 Poly Medicure Ltd.) 2009 2016 China Plant
Slide 6: Across the World, We serve people in over 125+ countries
Across the World, We serve people in over 125+ countries Our Growth Verticals POLYMED HQ Infusion Therapy & Dialysis & Transfusion Diagnostics MANUFACTURING UNITS Vascular Access Renal Care System PLAN1HEALTH NEW PLANTS SC- 2.00 mm x15 mm OUR PRESENCE Cardiology Oncology Critical Care 4 new Plants u
Slide 7: Board of Directors & Management
Board of Directors & Management Mr. Himanshu Baid Mr. Devendra Raj Mehta Mr. Rishi Baid (Managing Director) (Chairman, Non-Execu�ve (Joint Managing Director) Independent Director) Dr. Shailendra Raj Mehta Mr. Jugal Kishore Baid Mrs. Mukulika Baid (Non-Execu�ve) (Non-Execu�ve Director) (Non Execu�ve
Slide 8: Executive Global Leadership
Executive Global Leadership Building out Geographical Leadership with strong medical device experience & expertise Heyward Powe Xue Wendong VP Sales & Business General Manager , China Development, North & Central America Alessando Balboni Prof. Sergio Bertoglio • 20 years Medical Managing Director E
Slide 9: Leadership Team
Leadership Team Vishal Baid Naresh Vijay CFO & President, President-Finance Corporate Business Manish Sardana P K Gupta President, President, Operations India Business Hemant Bhalla Rajesh Kumar Sr. Vice President, Vice President, Renal Care Operations Sujit Gupta Arnab Basumallik SS Rawat Associate
Slide 10: Our Strength: Consistent all-round growth (Consolidated)
Our Strength: Consistent all-round growth (Consolidated) REVENUE (₹ Crores) EBIDTA (₹ Crores) PBT (₹ Crores) PAT (₹ Crores) 1115.23 923.06 269.38 237.49 786.20 195.24 179.28 214.34 213.10 180.04 135.84 146.51 FY 2021 FY 2022 FY 2023 Year Revenue CAGR Year EBIDTA % Year PBT % Year PAT % FY 2021 786.2
Slide 11: Financial Performance Q2 FY 2023
Financial Performance Q2 FY 2023 Growth Q2 F.Y 2022-23 Q2 (2023-24) Q1 (2023-24) Q2 (2022-23) 23 to Q2 24 % ` in Crores Revenue 22.78% Revenue 1115.23 337.29 320.83 274.70 Material cost 398.89 122.26 112.00 103.51 EBIDTA 36.38% Employee cost 178.15 50.88 49.29 44.37 PAT 42.97% R & D Expenses 17.80 5
Slide 12: Q2 FY 2023-24 Financial Trends
Q2 FY 2023-24 Financial Trends Revenue Revenue showed 22.78% growth during Q2 FY 2023-24 of Rs. 337.29 Crores 337.29 Cr. 274.70 Cr. in comparison to Rs. 274.70 Crores in Q2 FY 2022-23. Volume growth driven by: - Efforts to grow presence into emerging markets. - Quality improvement, Sales orientation
Slide 13: Q2 FY 2023-24 Financial Trends
Q2 FY 2023-24 Financial Trends Profit After Tax (PAT) 62.19 Cr. PAT showed 42.97% growth during Q2 FY 2023-24 of Rs. 62.19 Crores in comparison of Rs. 43.50 Crores in Q2 FY 2022-23. 43.50 Cr. PAT growth driven by: - Results reflect strategic progress realised against opportunity presented by the healt
Slide 14: Financial Performance Comparison
Financial Performance Comparison (Standalone & Consolidated) ( ` in lacs except per share data) Standalone Consolidated Quarter Half Year Quarter Quarter Half Year Quarter Ended Ended Ended Ended Ended Ended 30.09.2023 30.09.2023 30.09.2022 30.09.2023 30.09.2023 30.09.2022 (Unaudited) (Unaudited) (U
Slide 15: Way Forward
Way Forward … International Strategy Vascular Access • Transition to MDR • Be a leading global player • Improve Brand visibility in • Expand footprint in Europe International markets & USA 01 06 • Received US FDA 510(K) clearance for two products Renal Promote Infection • Introduce Indigenous 02 05
Slide 16: Shareholding Pattern 30 Sep, 2023
Shareholding Pattern 30 Sep, 2023 th OTH Promoters and 53.16 % 13% Promoters Group BC Mutual Funds 3.95 % 15% 30thSep, FPIs 14.49 % 2023 P & PG 53% Bodies Corporate 15.06 % FPI 14.49% Others 13.34 % MF 4% Grand total 100 % Confidential I Slide 16 www.polymedicure.com
Slide 17: Focus on Sustainability
Focus on Sustainability Augment the use of recycled Focus on Predictive & materials in packaging & Preventive maintenance cosistently strive to further to reduce down time of increase its usage machines Reduce energy consumption by Utilizing Automation producing & utilizing Tools, AI, IOT & Cobots r
Slide 18: Sustainability Reporting - Our Efforts
Sustainability Reporting - Our Efforts Water Consumption 14.5% Water Saving 18,690 KL Water Recycling by replacing DG set cooling towers with Close loop coil coolers Water reused in Gardening 65,544 KL/Year By reusing water in process system- Chillers, DG Sets, Cooling Towers, Steam Boilers, wash Ro
Slide 19: Corporate Communication
Corporate Communication India MedTech Expo by DoP, GOI at Gandhinagar Award for “Best Company in Innovation in Healthcare” Confidential I Slide 19 www.polymedicure.com
Slide 20: Thank You!
Poly Medicure Limited Registered Office: Thank You! 232 B, 3rd Floor, Okhla Industrial Estate, Phase III, New Delhi-110020, India Tel:- 91-11-33550700, 47317000, 26321838/99 For any general queries, Reach us at: info@polymedicure.com Visit: www.polymedicure.com Confidential I Slide 20 www.polymedicure